Iterum Therapeutics plc
ITRM
$0.69
$0.000.61%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 0.88% | 34.65% | |||
| Gross Profit | -0.88% | -34.65% | |||
| SG&A Expenses | 50.67% | 31.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 49.03% | 1.09% | |||
| Operating Income | -49.03% | -1.09% | |||
| Income Before Tax | -33.51% | 26.32% | |||
| Income Tax Expenses | -1.67% | 140.00% | |||
| Earnings from Continuing Operations | -33.08% | 25.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -33.08% | 25.69% | |||
| EBIT | -49.03% | -1.09% | |||
| EBITDA | -54.06% | 1.41% | |||
| EPS Basic | -13.51% | 41.77% | |||
| Normalized Basic EPS | -13.88% | 42.32% | |||
| EPS Diluted | -13.51% | 42.19% | |||
| Normalized Diluted EPS | -13.88% | 42.32% | |||
| Average Basic Shares Outstanding | 17.25% | 27.62% | |||
| Average Diluted Shares Outstanding | 17.25% | 27.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||